Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10911MR)

This product GTTS-WQ10911MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10911MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10146MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ12523MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15338MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ10501MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ5443MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ10985MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ10907MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ14902MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW